Indegene Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Indegene Ltd filed with BSE on 06 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Indegene reported Q1 FY27 revenue of INR10,631 million, up 39.7% year-on-year and 6% quarter-on-quarter, with EBITDA margin at 16.9%. Management attributed the margin decline from historical levels to workforce transformation investments and costs carried for Gen AI engagements like Tectonic where revenue is still ramping. The company said it expects organic growth in FY27 to exceed FY26, with margin recovery to the 19-20% range expected by the second half of the fiscal year.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue: INR10,631 million (Q1 FY27)
p. 4
“Q1 revenues came in at INR10,631 million, growing 39.7% year-on-year and 6% quarter-on-quarter.”
Manish Gupta, page 4 of the filed PDF · View the filing
Revenue in USD: USD 112.5 million (Q1 FY27)
p. 7
“Revenues for the quarter came in at INR10,631 million or USD 112.5 million, representing growth of 26.5% year-on-year and 2.5% quarter-on-quarter in U.S. dollar terms.”
Suhas Prabhu, page 7 of the filed PDF · View the filing
EBITDA: INR1,795 million (Q1 FY27)
p. 7
“Our EBITDA for the quarter was INR1,795 million at a margin of 16.9%.”
Suhas Prabhu, page 7 of the filed PDF · View the filing
PBT: INR1,527 million (Q1 FY27)
p. 8
“PBT came in at INR1,527 million, up 45.3% sequentially.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
Effective tax rate: 23.9% (Q1 FY27)
p. 8
“the effective tax rate for the quarter was at 23.9%.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
PAT: INR1,162 million (Q1 FY27)
p. 8
“PAT grew 45.9% sequentially to INR1,162 million at 10.9% of revenue, up approximately 300 basis points sequentially.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
Enterprise Commercial segment share: 70.6% (Q1 FY27)
p. 8
“Enterprise Commercial, our largest segment, contributed 70.6% of revenue.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
North America revenue share: 75.1% (Q1 FY27)
p. 8
“revenue and North America, our largest geography, 75.1%.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
Revenue from accounts beyond top 20: 33.4% of total revenue (Q1 FY27)
p. 8
“revenues from accounts beyond our top 20 has almost doubled year-on-year in rupee terms and now contributes 33.4% of total revenue.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
Active customer count: 105 (Q1 FY27)
p. 8
“Our active customer count rose sharply, up 14 sequentially to 105, a direct result of the sales and go-to-market investments we made last year.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
DSOs: 67 days (Q1 FY27)
p. 8
“the DSOs, net of unearned and unbilled revenue, was 67 days, up 4 days quarter-on-quarter.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
Cash and investments: INR14,602 million (Q1 FY27)
p. 8
“our cash and cash equivalents combined with investments remain strong at INR14,602 million.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
Revenue per employee: approximately $77,000 (trailing 12 months)
p. 4
“Our revenue per employee, something which we've been alluding to in all our calls now is approximately $77,000. On a trailing 12-month basis.”
Manish Gupta, page 4 of the filed PDF · View the filing
$10-25 million customer cohort: 9 (Q1 FY27)
p. 4
“we have added 2 customers to the $10 million to $25 million bucket, taking that cohort to 9.”
Manish Gupta, page 4 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA margin — 19% to 20% · H2 FY27
stated firmly by Suhas Prabhu
p. 9
“Through the inflection point in Q3 FY27, the EBITDA in H2 FY27 will be back in the range that we have operated in the past, that is 19% to 20%.”
Suhas Prabhu, page 9 of the filed PDF · View the filing
Margin normalization timing — Q4 FY27
stated firmly by Suhas Prabhu
p. 8
“With the current and anticipated momentum in FY27, we are on track. And the margin normalization is expected in 6 quarters, that is by Q4 of FY27.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
Organic revenue growth — FY27
stated firmly by Manish Gupta
p. 9
“On that basis, we expect our organic growth in FY27 to be better than FY26, and we anticipate an acceleration in the second half.”
Manish Gupta, page 9 of the filed PDF · View the filing
Outcome-based omnichannel engagement revenue recognition — Q3 FY27
stated firmly by Suhas Prabhu
p. 8
“And with revenue expected to be recognized starting Q3 FY27, it adds to our H2 revenues with costs already being incurred in the P&L.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said priorities are moving accounts up the customer pyramid and converting pipeline, while the main risk to watch is the regulatory and policy environment in the U.S.
Answered by Suhas Prabhu
Asked by Sucrit Patil: What are the top execution priorities and biggest risks in client adoption, regulatory shift, or competitive pressure?
p. 10
“What we keep a look out for is the regulatory environment and the policy decisions, especially in the U.S., which impacts this industry the most.”
Suhas Prabhu, page 10 of the filed PDF · View the filing
CFO said currency volatility impact should reduce due to hedge accounting adoption, and credit/receivable risk has historically been minimal.
Answered by Suhas Prabhu
Asked by Sucrit Patil: What financial risks does the company anticipate and how is it managing margins, cash flow, and receivables?
p. 10
“We continue to hedge, as we have in the past. And therefore, we believe that the currency volatility will not impact us at an operating margin level going forward.”
Suhas Prabhu, page 10 of the filed PDF · View the filing
Management clarified there is no delay and that the normalization timeline was actually shortened from a 6-8 quarter range to 6 quarters.
Answered by Manish Gupta
Asked by Prolin Nandu: Is there a delay in margin normalization, and what is the nature of the investment expenses being made?
p. 11
“We had got a range over there. We are saying we don't need this range. It's not going to be 6 to 8, it's going to be 6. By March end, we get back to that 19% to 20% range.”
Manish Gupta, page 11 of the filed PDF · View the filing
Management said it no longer breaks out BioPharm separately since it is integrated, and gave an approximate constant currency growth range.
Answered by Manish Gupta
Asked by Vinay Menon: What was organic growth this quarter and the BioPharm breakup, and what was constant currency growth?
p. 12
“We're not breaking up organic and inorganic growth from a BioPharm perspective, anymore.”
Manish Gupta, page 12 of the filed PDF · View the filing
Management said about 60% of contracts are output/outcome-based currently, and outlined typical 3-4 quarter ramp cycles for such deals.
Answered by Manish Gupta
Asked by Prakash Kapadia: What percentage of business is outcome-based and how does revenue flow from order book to P&L?
p. 13
“As a company, we already being operating in a 60-ish percent approximately output plus outcome-based contracts.”
Manish Gupta, page 13 of the filed PDF · View the filing
Management said this cannot be broken out because AI is embedded across all their offerings rather than being a separate line of business.
Answered by Manish Gupta
Asked by Chandan Kumar: What percentage of revenue comes from AI-led platform engagements?
p. 16
“unlike other companies, for us, AI is getting embedded in everything we do.”
Manish Gupta, page 16 of the filed PDF · View the filing
Management said net retention has exceeded 100% and renewal cycles typically span 3-5 years.
Answered by Manish Gupta
Asked by Chirag Kachhadiya: What is the typical annual renewal rate in the organic business?
p. 17
“Our net retention has been more than 100% for our customers.”
Manish Gupta, page 17 of the filed PDF · View the filing
Risks flagged
Regulatory and policy environment in the U.S. affecting the pharma industry
p. 10
“What we keep a look out for is the regulatory environment and the policy decisions, especially in the U.S., which impacts this industry the most.”
Suhas Prabhu, page 10 of the filed PDF · View the filing
Currency volatility from mark-to-market on undesignated forward contracts
p. 10
“Of course, the current undesignated hedges, which will still be material till December of this year is the only thing that we have to look out for from an accounting perspective.”
Suhas Prabhu, page 10 of the filed PDF · View the filing
Credit and receivable risk with biotech and emerging pharma clients
p. 11
“we have a strong governance process and innovative deal structures in our commercial terms when we engage with biotech and emerging pharma where the risk profile could be slightly different from the traditional ones.”
Suhas Prabhu, page 11 of the filed PDF · View the filing
Measured enterprise adoption pace of AI despite customer enthusiasm
p. 4
“What we are also seeing is that while the enthusiasm is real, enterprise adoption remains measured and the pace of change on the ground is slower.”
Manish Gupta, page 4 of the filed PDF · View the filing
Wage hike cycle impact on margins
p. 8
“both these factors will largely offset the impact from the annual wage hike cycle in our second quarter, thereby keeping our margins stable unlike the declining Q2 EBITDA margin that we have historically trended.”
Suhas Prabhu, page 8 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.